表紙
市場調查報告書
商品編碼
974871

癌症診斷市場 (血液癌症、乳癌、結腸直腸癌症、腎臟癌症、肝臟癌症、肺癌症):全球產業分析、市場規模、佔有率、成長、趨勢、預測 (2014-2020年)

Cancer Diagnostics Market (By Application-Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, & Others; By Method)-Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2014-2020

出版日期: | 出版商: Transparency Market Research | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球癌症診斷市場相關調查,全球市場概要,成長要素,市場趨勢,課題等的市場動態相關資訊,加上各市場區隔、各地區/國家的市場分析,並提供主要企業簡介等資訊。

目錄

第1章 序文

第2章 前提條件與調查手法

第3章 摘要整理:全球癌症診斷市場

第4章 市場概要

  • 簡介
    • 類型定義
    • 產業的演進/開發
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 全球癌症診斷市場分析與預測
    • 市場收益預測

第5章 重要考察

  • 法規方案、醫療費償付
  • 癌症的流行病學
  • 積極的市場參與企業的清單(供應商/分銷商/廠商/供應商)

第6章 全球癌症診斷市場分析與預測:各方法

  • 簡介和定義
    • 主要調查結果/發展
  • 全球癌症診斷市場規模預測 (以金額為準) :各方法
    • 切片檢查
    • 內視鏡檢驗
    • 成像
    • 腫瘤生物標記試驗
  • 全球癌症診斷市場魅力:各方法

第7章 全球癌症診斷市場分析與預測:各應用領域

  • 簡介和定義
    • 主要調查結果/發展
  • 全球癌症診斷市場規模預測 (以金額為準) :各應用領域
    • 血液癌症
    • 乳癌
    • 結腸直腸癌症
    • 腎臟癌症
    • 肝臟癌症
    • 肺癌症
    • 卵巢癌症
    • 胰臟癌症
    • 前列腺癌症
  • 全球癌症診斷市場魅力:各應用領域

第8章 全球癌症診斷市場分析與預測:各地區

  • 主要調查結果
  • 全球癌症診斷市場規模預測 (以金額為準) :各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 癌症診斷市場魅力

第9章 北美的癌症診斷市場分析與預測

  • 簡介
    • 主要調查結果
  • 北美的癌症診斷市場規模預測 (以金額為準) :各方法
  • 北美的癌症診斷市場規模預測 (以金額為準) :各應用領域
  • 北美的癌症診斷市場規模預測 (以金額為準) :各國
    • 美國
    • 加拿大
  • 北美的癌症診斷市場魅力分析
    • 各方法
    • 各應用領域
    • 各國

第10章 歐洲的癌症診斷市場分析與預測

第11章 亞太地區的癌症診斷市場分析與預測

第12章 南美的癌症診斷市場分析與預測

第13章 中東、非洲的癌症診斷市場分析與預測

第14章 競爭情形

  • 市場參與企業:競爭矩陣(企業等級、各規模)
  • 市場佔有率/地位分析:各企業
  • 競爭事業策略
  • 企業簡介
    • Abbott
    • Ambry Genetics
    • AstraZeneca plc
    • bioMeriux SA
    • Eli Lilly and Company
    • Genoptix, Inc
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd
    • Pfizer, Inc
目錄
Product Code: TMRGL3637

Title:
Cancer Diagnostics Market (By Application - Blood Cancer, Breast Cancer, Colorectal Cancer (CRC), Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer; By Method - Tumor Biomarker Tests (Prostate Specific Antigen Tests, Circulating Tumor Cells (CTC) Tests, Alpha-Fetoprotein (AFP) Tests, CA 19-9 Tests, CA 125 Tests, EGFR Mutation Tests, HER2 Tests, Carcinoembryonic Antigen (CEA) Tests, BRCA Tests, KRAS Mutation Tests, and Anaplastic Lymphoma Kinase (ALK) Tests), Imaging (Magnetic Resonance Imaging (MRI) Scan, Positron Emission Tomography (PET) Scan, Computed Tomography (CT) Scan, and Mammography), Endoscopy (Colonoscopy, Sigmoidoscopy, Bronchoscopy, and Colposcopy) , Biopsy(Bone Marrow Biopsy, Needle Biopsy, Endoscopic Biopsy)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020.

Global Cancer Diagnostics Market - Scope of Report

TMR's report on the global cancer diagnostics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global cancer diagnostics market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global cancer diagnostics market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global cancer diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global cancer diagnostics market.

The report delves into the competitive landscape of the global cancer diagnostics market. Key players operating in the global cancer diagnostics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global cancer diagnostics market that have been profiled in this report.

Key Questions Answered in Global Cancer Diagnostics Market Report

What is the scope of growth of product companies in the global cancer diagnostics market?

What will be the Y-o-Y growth of the global cancer diagnostics market between 2019 and 2027?

What is the influence of changing trends in technologies on the global cancer diagnostics market?

Will North America continue to be the most profitable market for cancer diagnostics providers?

Which factors are anticipated to hamper the growth of the global cancer diagnostics market during the forecast period?

Which are the leading companies in the global cancer diagnostics market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global cancer diagnostics market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global cancer diagnostics market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the cancer diagnostics market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the cancer diagnostics market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global cancer diagnostics market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global cancer diagnostics market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objective
  • 1.4. Research Highlight

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Type Definition
    • 4.1.2. Industry Evolution / Development
  • 4.2. Overview
  • 4.3. Market Dynamic
    • 4.3.1. Driver
    • 4.3.2. Restraint
    • 4.3.3. Opportunitie
  • 4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario and Reimbursement
  • 5.2. Cancer Epidemiology
  • 5.3. List of active market participants (suppliers/distributors/manufacturers/vendors)

6. Global Cancer Diagnostics Market Analysis and Forecast, by Method

  • 6.1. Introduction & Definition
    • 6.1.1. Key Findings / Development
  • 6.2. Global Cancer Diagnostics Market Value Forecast, by Method, 2017-2027
    • 6.2.1. Biopsy
      • 6.2.1.1. Bone Marrow Biopsy
      • 6.2.1.2. Needle Biopsy
      • 6.2.1.3. Endoscopic Biopsy
    • 6.2.2. Endoscopy
      • 6.2.2.1. Bronchoscopy
      • 6.2.2.2. Colonoscopy
      • 6.2.2.3. Sigmoidoscopy
      • 6.2.2.4. Colposcopy
      • 6.2.2.5. Other
    • 6.2.3. Imaging
      • 6.2.3.1. MRI Scan
      • 6.2.3.2. PET Scan
      • 6.2.3.3. CT Scan
      • 6.2.3.4. Mammography
      • 6.2.3.5. Ultrasound
    • 6.2.4. Tumor Biomarker Test
      • 6.2.4.1. PSA Test
      • 6.2.4.2. CTC Test
      • 6.2.4.3. AFP Test
      • 6.2.4.4. CA 19-9
      • 6.2.4.5. CA 125
      • 6.2.4.6. EGFR
      • 6.2.4.7. HER2
      • 6.2.4.8. CEA
      • 6.2.4.9. BRCA
      • 6.2.4.10. KRA
      • 6.2.4.11. ALK
  • 6.3. Global Cancer Diagnostics Market Attractiveness, by Method

7. Global Cancer Diagnostics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
    • 7.1.1. Key Findings / Development
  • 7.2. Global Cancer Diagnostics Market Value Forecast, by Application, 2017-2027
    • 7.2.1. Blood Cancer
    • 7.2.2. Breast Cancer
    • 7.2.3. Colorectal Cancer
    • 7.2.4. Kidney Cancer
    • 7.2.5. Liver Cancer
    • 7.2.6. Lung Cancer
    • 7.2.7. Ovarian Cancer
    • 7.2.8. Pancreatic Cancer
    • 7.2.9. Prostate Cancer
  • 7.3. Global Cancer Diagnostics Market Attractiveness, by Application

8. Global Cancer Diagnostics Market Analysis and Forecast, by Region

  • 8.1. Key Finding
  • 8.2. Global Cancer Diagnostics Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. North America Cancer Diagnostics Market Attractiveness, by Region

9. North America Cancer Diagnostics Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Finding
  • 9.2. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017-2027
    • 9.2.1. Biopsy
      • 9.2.1.1. Bone Marrow Biopsy
      • 9.2.1.2. Needle Biopsy
      • 9.2.1.3. Endoscopic Biopsy
    • 9.2.2. Endoscopy
      • 9.2.2.1. Bronchoscopy
      • 9.2.2.2. Colonoscopy
      • 9.2.2.3. Sigmoidoscopy
      • 9.2.2.4. Colposcopy
      • 9.2.2.5. Other
    • 9.2.3. Imaging
      • 9.2.3.1. MRI Scan
      • 9.2.3.2. PET Scan
      • 9.2.3.3. CT Scan
      • 9.2.3.4. Mammography
      • 9.2.3.5. Ultrasound
    • 9.2.4. Tumor Biomarker Test
      • 9.2.4.1. PSA Test
      • 9.2.4.2. CTC Test
      • 9.2.4.3. AFP Test
      • 9.2.4.4. CA 19-9
      • 9.2.4.5. CA 125
      • 9.2.4.6. EGFR
      • 9.2.4.7. HER2
      • 9.2.4.8. CEA
      • 9.2.4.9. BRCA
      • 9.2.4.10. KRA
      • 9.2.4.11. ALK
  • 9.3. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2027
    • 9.3.1. Blood Cancer
    • 9.3.2. Breast Cancer
    • 9.3.3. Colorectal Cancer
    • 9.3.4. Kidney Cancer
    • 9.3.5. Liver Cancer
    • 9.3.6. Lung Cancer
    • 9.3.7. Ovarian Cancer
    • 9.3.8. Pancreatic Cancer
    • 9.3.9. Prostate Cancer
  • 9.4. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2027
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Cancer Diagnostics Market Attractiveness Analysi
    • 9.5.1. By Method
    • 9.5.2. By Application
    • 9.5.3. By Country

10. Europe Cancer Diagnostics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Finding
  • 10.2. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017-2027
    • 10.2.1. Biopsy
      • 10.2.1.1. Bone Marrow Biopsy
      • 10.2.1.2. Needle Biopsy
      • 10.2.1.3. Endoscopic Biopsy
    • 10.2.2. Endoscopy
      • 10.2.2.1. Bronchoscopy
      • 10.2.2.2. Colonoscopy
      • 10.2.2.3. Sigmoidoscopy
      • 10.2.2.4. Colposcopy
      • 10.2.2.5. Other
    • 10.2.3. Imaging
      • 10.2.3.1. MRI Scan
      • 10.2.3.2. PET Scan
      • 10.2.3.3. CT Scan
      • 10.2.3.4. Mammography
      • 10.2.3.5. Ultrasound
    • 10.2.4. Tumor Biomarker Test
      • 10.2.4.1. PSA Test
      • 10.2.4.2. CTC Test
      • 10.2.4.3. AFP Test
      • 10.2.4.4. CA 19-9
      • 10.2.4.5. CA 125
      • 10.2.4.6. EGFR
      • 10.2.4.7. HER2
      • 10.2.4.8. CEA
      • 10.2.4.9. BRCA
      • 10.2.4.10. KRA
      • 10.2.4.11. ALK
  • 10.3. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2027
    • 10.3.1. Blood Cancer
    • 10.3.2. Breast Cancer
    • 10.3.3. Colorectal Cancer
    • 10.3.4. Kidney Cancer
    • 10.3.5. Liver Cancer
    • 10.3.6. Lung Cancer
    • 10.3.7. Ovarian Cancer
    • 10.3.8. Pancreatic Cancer
    • 10.3.9. Prostate Cancer
  • 10.4. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Europe Cancer Diagnostics Market Attractiveness Analysi
    • 10.5.1. By Method
    • 10.5.2. By Application
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Cancer Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Finding
  • 11.2. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017-2027
    • 11.2.1. Biopsy
      • 11.2.1.1. Bone Marrow Biopsy
      • 11.2.1.2. Needle Biopsy
      • 11.2.1.3. Endoscopic Biopsy
    • 11.2.2. Endoscopy
      • 11.2.2.1. Bronchoscopy
      • 11.2.2.2. Colonoscopy
      • 11.2.2.3. Sigmoidoscopy
      • 11.2.2.4. Colposcopy
      • 11.2.2.5. Other
    • 11.2.3. Imaging
      • 11.2.3.1. MRI Scan
      • 11.2.3.2. PET Scan
      • 11.2.3.3. CT Scan
      • 11.2.3.4. Mammography
      • 11.2.3.5. Ultrasound
    • 11.2.4. Tumor Biomarker Test
      • 11.2.4.1. PSA Test
      • 11.2.4.2. CTC Test
      • 11.2.4.3. AFP Test
      • 11.2.4.4. CA 19-9
      • 11.2.4.5. CA 125
      • 11.2.4.6. EGFR
      • 11.2.4.7. HER2
      • 11.2.4.8. CEA
      • 11.2.4.9. BRCA
      • 11.2.4.10. KRA
      • 11.2.4.11. ALK
  • 11.3. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2027
    • 11.3.1. Blood Cancer
    • 11.3.2. Breast Cancer
    • 11.3.3. Colorectal Cancer
    • 11.3.4. Kidney Cancer
    • 11.3.5. Liver Cancer
    • 11.3.6. Lung Cancer
    • 11.3.7. Ovarian Cancer
    • 11.3.8. Pancreatic Cancer
    • 11.3.9. Prostate Cancer
  • 11.4. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Asia Pacific Cancer Diagnostics Market Attractiveness Analysi
    • 11.5.1. By Method
    • 11.5.2. By Application
    • 11.5.3. By Country/Sub-region

12. Latin America Cancer Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Finding
  • 12.2. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017-2027
    • 12.2.1. Biopsy
      • 12.2.1.1. Bone Marrow Biopsy
      • 12.2.1.2. Needle Biopsy
      • 12.2.1.3. Endoscopic Biopsy
    • 12.2.2. Endoscopy
      • 12.2.2.1. Bronchoscopy
      • 12.2.2.2. Colonoscopy
      • 12.2.2.3. Sigmoidoscopy
      • 12.2.2.4. Colposcopy
      • 12.2.2.5. Other
    • 12.2.3. Imaging
      • 12.2.3.1. MRI Scan
      • 12.2.3.2. PET Scan
      • 12.2.3.3. CT Scan
      • 12.2.3.4. Mammography
      • 12.2.3.5. Ultrasound
    • 12.2.4. Tumor Biomarker Test
      • 12.2.4.1. PSA Test
      • 12.2.4.2. CTC Test
      • 12.2.4.3. AFP Test
      • 12.2.4.4. CA 19-9
      • 12.2.4.5. CA 125
      • 12.2.4.6. EGFR
      • 12.2.4.7. HER2
      • 12.2.4.8. CEA
      • 12.2.4.9. BRCA
      • 12.2.4.10. KRA
      • 12.2.4.11. ALK
  • 12.3. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2027
    • 12.3.1. Blood Cancer
    • 12.3.2. Breast Cancer
    • 12.3.3. Colorectal Cancer
    • 12.3.4. Kidney Cancer
    • 12.3.5. Liver Cancer
    • 12.3.6. Lung Cancer
    • 12.3.7. Ovarian Cancer
    • 12.3.8. Pancreatic Cancer
    • 12.3.9. Prostate Cancer
  • 12.4. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America Latin America
  • 12.5. Latin America Cancer Diagnostics Market Attractiveness Analysi
    • 12.5.1. By Method
    • 12.5.2. By Application
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Finding
  • 13.2. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017-2027
    • 13.2.1. Biopsy
      • 13.2.1.1. Bone Marrow Biopsy
      • 13.2.1.2. Needle Biopsy
      • 13.2.1.3. Endoscopic Biopsy
    • 13.2.2. Endoscopy
      • 13.2.2.1. Bronchoscopy
      • 13.2.2.2. Colonoscopy
      • 13.2.2.3. Sigmoidoscopy
      • 13.2.2.4. Colposcopy
      • 13.2.2.5. Other
    • 13.2.3. Imaging
      • 13.2.3.1. MRI Scan
      • 13.2.3.2. PET Scan
      • 13.2.3.3. CT Scan
      • 13.2.3.4. Mammography
      • 13.2.3.5. Ultrasound
    • 13.2.4. Tumor Biomarker Test
      • 13.2.4.1. PSA Test
      • 13.2.4.2. CTC Test
      • 13.2.4.3. AFP Test
      • 13.2.4.4. CA 19-9
      • 13.2.4.5. CA 125
      • 13.2.4.6. EGFR
      • 13.2.4.7. HER2
      • 13.2.4.8. CEA
      • 13.2.4.9. BRCA
      • 13.2.4.10. KRA
      • 13.2.4.11. ALK
  • 13.3. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2027
    • 13.3.1. Blood Cancer
    • 13.3.2. Breast Cancer
    • 13.3.3. Colorectal Cancer
    • 13.3.4. Kidney Cancer
    • 13.3.5. Liver Cancer
    • 13.3.6. Lung Cancer
    • 13.3.7. Ovarian Cancer
    • 13.3.8. Pancreatic Cancer
    • 13.3.9. Prostate Cancer
  • 13.4. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. GCC Countrie
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Cancer Diagnostics Market Attractiveness Analysi
    • 13.5.1. By Method
    • 13.5.2. By Application
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by Tier and Size of companies)
  • 14.2. Market Share / Position Analysis, by Company, 2018
  • 14.3. Competitive Business Strategie
  • 14.4. Company Profile
    • 14.4.1. Abbott
      • 14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.1.2. Growth Strategie
      • 14.4.1.3. SWOT Analysi
    • 14.4.2. Ambry Genetics
      • 14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.2.2. Growth Strategie
      • 14.4.2.3. SWOT Analysi
    • 14.4.3. AstraZeneca plc
      • 14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.3.2. Growth Strategie
      • 14.4.3.3. SWOT Analysi
    • 14.4.4. bioMeriux SA
      • 14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.4.2. Growth Strategie
      • 14.4.4.3. SWOT Analysi
    • 14.4.5. Eli Lilly and Company
      • 14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.5.2. Growth Strategie
      • 14.4.5.3. SWOT Analysi
    • 14.4.6. Genoptix, Inc
      • 14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.6.2. Growth Strategie
      • 14.4.6.3. SWOT Analysi
    • 14.4.7. GlaxoSmithKline plc
      • 14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.7.2. Growth Strategie
      • 14.4.7.3. SWOT Analysi
    • 14.4.8. F. Hoffmann-La Roche Ltd
      • 14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.8.2. Growth Strategie
      • 14.4.8.3. SWOT Analysi
    • 14.4.9. Pfizer, Inc
      • 14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.4.9.2. Growth Strategie
      • 14.4.9.3. SWOT Analysis

List of Table

  • Table 1List of Abbreviation
  • Table 2Market Snapshot: Global Cancer Diagnostics Market
  • Table 3List of Cancer Risk Factors
  • Table 4Estimated Incidence, 1 year, 2 years and 5 years survival
  • Table 5Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
  • Table 6Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
  • Table 7Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
  • Table 8Summary of Type of Diagnostics Test in the U.S.
  • Table 9Event Impact Analysis: Global Cancer Diagnostics Market, 2017-2027
  • Table 10Global Cancer Diagnostics Market Revenue, by Method, 2017-2027 (USD) Million
  • Table 11Global Cancer Diagnostics Market Revenue, by Application, 2017-2027 (USD) Million
  • Table 12Global Cancer Diagnostics Market Revenue, by Geography, 2017-2027 (USD) Million

List of Figure

  • Figure 1.Global Cancer Diagnostics Market Segmentation
  • Figure 2.Global Cancer Diagnostics Market, by Application, 2018 (USD Million)
  • Figure 3.Comparative Analysis: Global Cancer Diagnostics Market, by Geography, 2018 & 2027E (Value %)
  • Figure 4.Porter's Five Forces Analysis: Global Cancer Diagnostics Market
  • Figure 5.Market Attractiveness Analysis: Global Cancer Diagnostics Market, By Method, 2018 & 2027 (Value %)
  • Figure 6.Cancer Diagnostics Market: Global Market Share by Key Players, IVDs, Molecular Diagnostics and Companion Diagnostics), 2018 (Value %)
  • Figure 7.Cancer Diagnostics Market: Global Market Share by Key Players, 2018 (Value %)
  • Figure 8.Global Prostate Specific Antigen Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 9.Global Circulating Tumor Cells (CTC) Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 10.Global Alpha-Fetoprotein (AFP) Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 11.Global CA 19-9 Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 12.Global CA-125 Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 13.Global EGFR Mutation Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 14.Global HER2 Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 15.Global Carcinoembryonic Antigen (CEA) Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 16.Global BRCA Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 17.Global KRAS Mutation Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 18.Global Anaplastic Lymphoma Kinase (ALK) Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 19.MRI Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
  • Figure 20.PET Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
  • Figure 21.CT Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
  • Figure 22.Mammography Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
  • Figure 23.Ultrasound Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
  • Figure 24.Global Colonoscopy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 25.Global Sigmoidoscopy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 26.Global Bronchoscopy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 27.Global Colposcopy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 28.Global Other Endoscopy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 29.Global Bone Marrow Biopsy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 30.Global Needle Biopsy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 31.Global Endoscopic Biopsy Tests Market Revenue, 2017-2027 (USD Million)
  • Figure 32.Comparative analysis: Global Cancer Diagnostics Market, by Applications, 2018 & 2027 (Value %)
  • Figure 33.Blood Cancer: Estimated number of new cases, all ages, both sexes (2012, 2015 & 2027)
  • Figure 34.Global Blood Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
  • Figure 51.Comparative Analysis: Global Cancer Diagnostics Market, By Geography, 2018 & 2027 (Value %)
  • Figure 52.North America Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
  • Figure 53.Europe Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
  • Figure 54.Asia Pacific Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
  • Figure 55.Rest of the World Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
  • Figure 56.Abbott Laboratories : Annual Revenue, (USD Million)
  • Figure 57.Astra Zeneca plc: Annual Revenue, (USD Million)
  • Figure 58.bioMeriux SA : Annual Revenue, (USD Million)
  • Figure 59.Eli Lilly and Company: Annual Revenue, (USD Million)
  • Figure 60.GlaxoSmithKline plc: Annual Revenue, (USD Million)
  • Figure 61.F. Hoffmann-La Roche Ltd: Annual Revenue, (USD Million)
  • Figure 62.Pfizer, Inc.: Annual Revenue, (USD Million)